Analyst Update: Royal Caribbean, Take-Two, Alder Biopharma

Analysts adjusted their ratings on Royal Caribbean Cruises Ltd (NYSE:RCL), Take-Two Interactive Software, Inc. (NASDAQ:TTWO), and Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

Jun 24, 2015 at 1:58 PM
facebook X logo linkedin


Analysts are weighing in today on cruise concern Royal Caribbean Cruises Ltd (NYSE:RCL), gaming giant Take-Two Interactive Software, Inc. (NASDAQ:TTWO), and drugmaker Alder Biopharmaceuticals Inc (NASDAQ:ALDR). Here's a quick roundup of today's brokerage notes on RCL, TTWO, and ALDR.

  • Goldman Sachs upgraded its opinion of RCL to "buy" from "neutral," citing the company's improving traction in China and the stock's "compelling entry point" relative to its peers. As such, the shares have managed to buck the broad-market trend lower, edging up 0.2% to $80.65. On a longer-term basis, though, Royal Caribbean Cruises Ltd has struggled, sitting 2.2% below its year-to-date flatline. It's worth noting that Goldman isn't alone in its glowing recommendation of the stock. In fact, 13 analysts current rate RCL a "buy" or better, compared to one "hold" assessment and not a single "sell."

  • Jefferies weighed in on a number of video game names today, including TTWO. Specifically, the brokerage firm upgraded the equity to "buy" from "hold," and boosted its price target to $35 from $29. The bullish note has led Take-Two Interactive Software, Inc. to a 1.3% intraday lead at $28.38. In fact, since hitting a late-April low of $23.30, the shares have advanced 22%. Nevertheless, traders have been buying to open puts over calls at an accelerated clip of late. TTWO's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.61 ranks in the 82nd percentile of its annual range. Likewise, the stock's Schaeffer's put/call open interest ratio (SOIR) sits at 1.13 -- higher than 99% of comparable readings from the past year.

  • Unlike this pair of struggling sector peers, ALDR is 5.6% higher this afternoon at $50.22. Earlier, the stock touched a record high of $51.43 after Credit Suisse initiated coverage with an "outperform" endorsement and $50 price target, citing the company's potentially "best-in-class" migraine drug. The upward price action is more of the same for Alder Biopharmaceuticals Inc, which has surged 72.5% in 2015. Not everyone's so confident in the stock, though -- 11.2% of its float is currently sold short.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI